论文部分内容阅读
目的:探讨化疗配合加速分割放疗对于Ⅲ和ⅣA期鼻咽癌患者的治疗效果,观察其临床疗效,探讨其应用价值。方法:对于2009年1月～2011年6月在本院进行治疗的76例Ⅲ和ⅣA期鼻咽癌患者,随机分为两组,一组为化疗法(对照组),一组为化疗配合加速分割放疗法(观察组),对两组患者治疗后的有效率进行比较。结果:化疗配合加速分割放疗组中,痊愈有9例,显效15例,有效10例,无效4例,有效率为89.5%;化疗组中,痊愈有6例,显效12例,有效8例,无效12例,有效率为68.4%;两组有效率进行比较,采用卡方检验进行统计分析,两组间具有统计学差异(P<0.05);两组患者治疗后的不良反应:观察组患者白细胞下降为3.12%,对照组患者白细胞下降为3.04%,两组间不存在统计学差异(P>0.05);观察组和对照组患者发生急性放射性口咽黏膜的几率分别为60.1%和42.6%,两组间具有统计学差异(P<0.05)。结论:化疗配合加速分割放疗对于Ⅲ和ⅣA期鼻咽癌患者治疗效果较好,其有效率高于单纯化疗组,同时其不良反应与化疗组相似,具有很好的临床应用价值。
Objective: To investigate the effect of chemotherapy combined with accelerated radiotherapy for the treatment of patients with stage Ⅲ and ⅣA nasopharyngeal carcinoma, and to observe its clinical efficacy and explore its value. Methods: A total of 76 patients with stage Ⅲ and ⅣA nasopharyngeal carcinoma who were treated in our hospital from January 2009 to June 2011 were randomly divided into two groups, one was chemotherapy (control group), the other was chemotherapy plus Accelerated fractionated radiotherapy (observation group), the comparison of the two groups of patients after treatment efficiency. Results: In the chemotherapy combined with accelerated radiotherapy and radiotherapy group, 9 cases were cured, 15 cases were markedly effective, 10 cases were effective, 4 cases were ineffective, and the effective rate was 89.5%. In the chemotherapy group, 6 cases were cured, 12 cases markedly effective, 8 cases effective, Ineffective in 12 cases, the effective rate was 68.4%; two groups were compared for efficiency, using chi-square test for statistical analysis, there was a significant difference between the two groups (P <0.05); two groups of patients adverse reactions after treatment: observation group patients The leukopenia was 3.12% in the control group and 3.04% in the control group. There was no significant difference between the two groups (P> 0.05). The incidences of acute oropharyngeal mucosa in the observation group and control group were 60.1% and 42.6% , With statistical difference between the two groups (P <0.05). Conclusion: Chemotherapy combined with accelerated radiotherapy for patients with stage Ⅲ and ⅣA nasopharyngeal carcinoma treatment is better, the effective rate is higher than the chemotherapy group, and its adverse reactions are similar to the chemotherapy group, with good clinical value.